Actively Recruiting
Accelerated TMS for Apathy in PD
Led by Medical University of South Carolina · Updated on 2026-03-27
15
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This single-site, open-label pilot study will evaluate the feasibility, tolerability, and preliminary efficacy of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants with PD and clinically significant apathy will undergo six treatment visits over two weeks, receiving eight iTBS sessions per day. Outcomes include adherence, tolerability, changes in apathy (Lille Apathy Rating Scale), functional engagement, and neural target engagement assessed via resting-state fMRI and EEG. Follow-up assessments will occur at two and four weeks post-treatment.
CONDITIONS
Official Title
Accelerated TMS for Apathy in PD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 45 and 85 years
- Diagnosis of Parkinson's Disease
- Apathy Evaluation Scale (AES) score of 37 or higher
- Stable Parkinson's Disease medications
- Caregiver informant available
You will not qualify if you...
- Contraindications to MRI or TMS
- Severe cognitive impairment with MoCA score less than 21
- Psychiatric disorders such as bipolar disorder, schizophrenia, or active substance use disorder
- History of seizures
- Acute suicidality or suicide attempt within the past year
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here